AAS
RANI icon

Ameritas Advisory Services’s Rani Therapeutics RANI Stock Holding History

Ameritas Advisory Services’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-280
Closed -$144 – 2743
2025
Q2 		$144 Buy
+280
New +$228 ﹤0.01% 2775

Other funds holding RANI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Ameritas Advisory Services's RANI Position: Q3 2025 in Review

Ameritas Advisory Services sold out of Rani Therapeutics (RANI) in Q3 2025, closing a stake of 280 shares — an estimated $144 sold.

Ameritas Advisory Services first reported a position in RANI in Q2 2025 and held it in 1 quarter. The position peaked at $144 in Q2 2025. 38 funds tracked by Wall St. Rank hold RANI as of Q3 2025.

  • Ameritas Advisory Services reported no remaining Rani Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ameritas Advisory Services sold 280 Rani Therapeutics shares in Q3 2025, an estimated $144.
  • Ameritas Advisory Services first reported a position in Rani Therapeutics in Q2 2025 and held it in 1 quarter.
  • Ameritas Advisory Services's Rani Therapeutics position peaked at $144 in Q2 2025.
  • 38 funds tracked by Wall St. Rank held Rani Therapeutics as of Q3 2025.

Based on Ameritas Advisory Services's 13F filing for Q3 2025, filed 6 Nov 2025.